In the following year, the group founded a wholly-owned subsidiary based in Mumbai, India providing access to the Indian market for the sale and distribution for the Group companies' products.
In 2012, we announced that we has entered into agreements providing worldwide exclusive access to two point of care (POC) tests for CD4 and Syphilis developed by Burnet Institute in Melbourne, Australia. Testing for the number of CD4 T+ cells is a vital component for the management and care of people suffering from HIV and is required to determine when HIV patients should commence antiretroviral treatment (ART). The current market for monitoring of CD4 T+ cells is dominated by expensive and complex technology which is a bottleneck to commencing ART particularly for HIV patients living in rural areas. There is a clear unmet need for a lower cost POC test that can be conducted in doctors' surgeries and outreach clinics in resource-poor settings.
In 2018, a restructure of our operations was carried out whereby our four UK companies were amalgamated into one entity, Omega Diagnostics Ltd. Further to this, in 2018 we disposed of our infectious disease business, with the exception of VISITECT CD4, to Novacyt SA, an international specialist in clinical diagnostics.
In early 2022, we implemented a revised strategy to reduce operating costs through the sale of the Alva site, exit the Global Health business and to invest in our Health and Nutrition business in order to drive growth. We are now focused on creating value by increasing the footprint of our food sensitivity products, particularly in the US and China, where we see opportunities for growth in direct-to-consumer market channels and broadening the range of products available in our Health and Nutrition division.
Shares in the Company are not traded anywhere other than AIM
Last updated 30 September 2022